514429-364

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

Kissel et al.

U.S. Serial No.

Continuation of US Appln Serial No. 09/162,101

For

BIOLOGICALLY TOLERATED LOW

MOLECULAR WEIGHT POLYETHYLENIMINES

Filed

Herewith

Examiner

Not Yet Known

Group Art Unit

Not Yet Known

745 Fifth Avenue New York, NY 10151

EXPRESS MAIL Mailing Label Number: EL5882755995US

Date of Deposit: September 22, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Trademarks, 2900 Crystal Drive Arlington,

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants wish to bring the prior publications cited on the enclosed Form PTO-1449 (in duplicate) to the attention of the Examiner. The relevance of these prior publications is that they were cited during the prosecution of the parent application, Application USSN 09/162,101. Applicants request that the Examiner consider these publications and return a copy of the initialed Form PTO-1449 to Applicants.



U.S. PATENTS

DOCUM	ENT NO.	DATE ISSUED	FIRST INVENTOR
1. 6,013,240	1/	00	Behr et al.
2. 5,830,730	11	/1998	German et al.
3. 6,036,955	3/	14/00	Thorpe et al.
4. 5,977,307	11	/2/99	Friden et al.
5. 5,919,442	7/	6/99	Yin et al.
6. 4,690,985	9/	1/87	Tomalia et al.
7. 5,714,166	2/	3/98	Tomalia et al.

REFERENCES

- 8. Abdallah et al., Hum. Gene Ther., Vol. 7, 1996, pp. 1947-1954;
- 9. Behr, Bioconjugate Chem., Vol. 5, 1994, pp. 382-389;
- 10. Behr, Chimia, Vol. 51, 1997, pp. 34-36;
- 11. Boussif et al., Gene Therapy, Vol. 3, 1996, pp. 1074-1080;
- 12. Boussif et al., Proc. Natl. Acad. Sci., Vol. 92, 1995, pp. 7297-7301;
- 13. Cherng et al., Pharm. Res., Vol. 13, No. 7, 1996, pp. 1038-1042;
- 14. Choksakulnimitr et al., J. Control. Rel., Vol. 34, 1995, pp. 233-241;
- 15. Cotten et al., Meth. in Enzymol., Vol. 217, 1993, pp. 618-644;
- 16. Crystal, Science, Vol. 270, 1995, pp. 404-410;
- 17. Dick et al., J. Macromol. Sci., Vol. A4, 1970, pp. 1301-1314;
- 18. European Patent No. 0790312 A2 dated August 20, 1997;
- 19. Gao et al., Gene Therapy, Vol. 2, 1995, pp. 710-722;
- 20. German Patent Appln. No. 19649645.4
- 21. Gopal, Mol. Cell. Biol., Vol. 5, 1985, pp. 1188-1193;
- 22. Haensler et al., Bioconjugate Chem., Vol. 4, 1993, pp. 372-379;
- 23. Midoux et al., Nucleic Acids Research, Vol. 21, No. 4, 1993, pp. 871-878;



- 24. Miller, Nature, Vol. 357, 1992, pp. 455-460;
- 25. Mischeck et al., Cell. Tiss. Res., Vol. 256, 1989, pp. 221-226;
- 26. Mosmann, J. Immunol. Methods, Vol. 65, 1983, pp. 55-63;
- 27. Mulligan, Science, Vol. 260, 1993, pp. 926-932;
- 28. Remy et al., J. Lip. Res., Vol. 6, No. 3, 1996, pp. 535-544;
- 29. Tomlinson et al., J. of Contr. Rel., Vol. 39, 1996, pp. 357-372
- 30. Trubetskoy et al., Bioconjugate Chem., Vol. 3, 1992, pp. 323-327;
- 31. Vollmert, Grudriss der Makromdekularen Chemie, Springer Verlag Berlin, 1962, pp. 216-225;
- 32. Wagner et al., Proc. Natl. Acad. Sci., Vol. 87, 1990, pp. 3410-3414;
- 33. Wenker, JACS, Vol. 57, 1935, pp. 2328-2329;
- 34. International Patent No. WO 96/02655 dated February 1, 1996;
- 35. Wolfert et al., Hum. Gene Ther., Vol. 7, 1996, pp. 2123-2133;
- 36. Wu et al., Biotherapy, Vol. 3, 1991, pp. 87-95;
- 37. Wu et al., J. Biol. Chem., Vol. 262, No. 10, 1987, pp. 4429-4432; and
- 38. Zenke et al., Proc. Natl. Acad. Sci., Vol. 87, 1990, pp. 3655-3659.

It is believed that no fee is due. If, however, a fee is due, the Assistant

Commissioner is authorized to charge such fee to Deposit Account No. 50-0320.

Favorable action is earnestly solicited.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

Attorneys for Applicants

Peter J Waibel

Registration No. 43.228

(212) 588-0800